Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2500462 | Farmacia Hospitalaria | 2008 | 11 Pages |
Abstract
Currently, the hepatitis C treatment in the liver transplantation setting is based on the use of peginterferon associated with ribavirin as pre-transplant treatment in selected patients or as treatment of recurrent post-transplant hepatitis C, achieving sustained virological responses of around 20% and 35% respectively. The main limitation of these treatments is the high frequency of the adverse effects and interruptions to treatment, meaning it is important to carry out strict follow-up of the treatment safety.
Keywords
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Pharmaceutical Science
Authors
L. Margusino Framiñán, F. Suárez López, I. MartÃn Herranz,